INTRODUCTION
============

Obesity is a major health problem, with a rapidly increasing prevalence in Asian populations as well as in Western countries \[[@b1-ce-2016-140]\]. In Korea, the prevalence of obesity was 26.9% in 1998 and 32.0% in 2011; a significantly increased overall prevalence of obesity and abdominal obesity by 1.19-fold and 1.24-fold, respectively, occurred from 2001 to 2011 \[[@b2-ce-2016-140]\]. Serious chronic diseases including diabetes mellitus (DM), hypertension, coronary heart disease, and malignancy can develop if obesity is not treated properly. Unfortunately, however, the long-term results of non-surgical treatments, such as lifestyle modification, diet, and pharmacologic intervention, are unsatisfactory in severe, class III obesity (body mass index \[BMI\] \>40 kg/m^2^), which requires surgical treatment in most cases \[[@b3-ce-2016-140]\].

Typical bariatric surgical procedures include Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion and duodenal switch (BPD-DS), laparoscopic adjustable gastric banding (LAGB), and sleeve gastrectomy (SG), which result in greater sustained weight reduction, lower incidence of type 2 DM, and lipid improvement during the long-term follow-up period over 5 years compared to non-surgical approaches \[[@b4-ce-2016-140]\]. These procedures are now being performed globally as standard therapeutic interventions for severe obesity. However, increasing numbers of perioperative or late postoperative complications of bariatric surgery, such as anastomotic leak, bleeding, stricture, marginal ulcers, dilation of gastrojejunal (GJ) anastomosis or gastric pouch, and band erosions, have been accumulating; these complications can be life-threatening if not managed promptly \[[@b5-ce-2016-140]\]. Accurate diagnosis and decision-making regarding reoperation is essential. However, the surgical approach may present a significant clinical burden for many patients, especially those with severe comorbidities and thus a high operative risk. In this situation, endoscopic therapy can be a useful alternative option for the feasible and safe management of postoperative complications associated with bariatric surgery.

This review provides an update of recent pivotal clinical outcomes and future perspectives of endoscopic management of post-bariatric surgical complications.

LEAK AND FISTULA
================

Gastrointestinal (GI) leak after bariatric surgery is one of the most life-threatening complications, with a mortality rate of 14% \[[@b6-ce-2016-140]\]. The incidence of leak after bariatric surgery is 2.4%--4.9% and varies according to the type of surgery \[[@b6-ce-2016-140]-[@b8-ce-2016-140]\]. The most frequent site of leak in patients with RYGB is the GJ anastomosis, followed by the gastric pouch and jejunojejunal anastomosis \[[@b8-ce-2016-140]\], whereas in a vast majority of patients with SG, the location of the leak is proximal, near the esophagogastric junction (EGJ) \[[@b7-ce-2016-140]\]. Leaks are classified according to the time of occurrence: early (\<14 days postoperative), intermediate (2--6 weeks), and late or delayed (\>6 weeks). Most post-bariatric leaks occur early. Early leaks in hemodynamically unstable patients, such as those with tachycardia, tachypnea, dyspnea, and fever, should be treated immediately, and usually require surgical cleansing with external drainage as well as basic conservative management, such as fasting, total parenteral nutrition, and administration of intravenous antibiotics. However, in cases of late or delayed leaks, non-surgical management, such as percutaneous or internal drainage using the GI tract rather than surgical debridement, may be an alternative option. Several case reports or case series regarding endoscopic drainage of postoperative fluid collection or abscess have been published. Removal of an infected abscess is performed by transluminal debridement with endoscopic aspiration and placement of a nasocystic catheter \[[@b9-ce-2016-140]\], or intraluminal traction of a migrated band in patients with abdominal abscess due to early migration of an adjustable gastric band \[[@b10-ce-2016-140]\]. A recent study demonstrated the clinical feasibility of trans-fistula drainage of an infected cyst by insertion of a double-pigtail plastic stent in 26 patients with recurrent fluid collection despite placement of a self-expandable metal stent (SEMS), showing a 79% clinical success rate \[[@b11-ce-2016-140]\]. Another novel technique for endoscopic internal drainage is vacuum-assisted closure, a procedure based on the insertion of a sponge in the cavity to absorb the infected fluid and accelerate the formation of granulation tissue and closure of the infected cyst. Two case series that have been published to evaluate the feasibility of vacuum-assisted endoscopic drainage for the treatment of leak after gastroesophageal surgery showed high clinical success rates ranging from 85% to 100% \[[@b12-ce-2016-140],[@b13-ce-2016-140]\].

Postoperative leak may persist even after adequate drainage of collected fluid, and further management should then be considered. In addition to drainage, there are two other main categories of endoscopic procedures related to the management of postoperative leak: coverage or closure of the defect \[[@b14-ce-2016-140]\]. However, internal/external drainage and removal of collected fluid should precede or be combined with coverage or closure of the defect to prevent the formation of sealed-off abscesses. To cover the defect, endoscopic stent insertion has been widely performed. In particular, newly developed, partially or fully covered SEMS that are flexible and maintain patency of a narrow GI lumen, combined with a delivery system for through-the-scope (TTS) placement via a working channel, enable endoscopists to insert stents under direct inspection of the target area \[[@b15-ce-2016-140]\]. [Table 1](#t1-ce-2016-140){ref-type="table"} summarizes the previous studies regarding clinical outcomes and complications of SEMS insertion for treatment of post-bariatric surgery leaks. The majority of bariatric surgeries are RYGB and SG, and partially covered SEMS have usually been used \[[@b16-ce-2016-140]-[@b24-ce-2016-140]\]. The duration of stenting varies, with the median period ranging from 3 to 10 weeks \[[@b17-ce-2016-140],[@b18-ce-2016-140],[@b20-ce-2016-140]-[@b23-ce-2016-140]\]. However, two studies showed that the SEMS was maintained for less than 2 weeks in more than two-thirds of patients \[[@b19-ce-2016-140],[@b24-ce-2016-140]\]. The clinical success rate of the procedure, which indicates complete closure of leak or fistular opening, has been acceptable, ranging from 65% to 95% \[[@b16-ce-2016-140]-[@b24-ce-2016-140]\]. Overall, the clinical success of stent insertion is significantly associated with shorter delay between bariatric surgery and stent insertion, because delayed stenting may lead to fibrous change and chronic fistula formation from acute leaks, and eventually to a higher failure rate of closure of leaks. Another important factor is larger leak size (≥10 mm) \[[@b14-ce-2016-140]\].

In terms of complications, stent migration occurs most frequently. Its reported rate of occurrence varies widely, from 5% to 62% \[[@b16-ce-2016-140]-[@b24-ce-2016-140]\], and more serious complications, such as perforation, have also been reported \[[@b20-ce-2016-140],[@b22-ce-2016-140]\]. A previous meta-analysis regarding the use of SEMS in the treatment of post-bariatric surgery leaks reported an 88% clinical success rate, and successful endoscopic stent removal was achieved in 92% of cases, while stent migration was observed in 17% of cases \[[@b25-ce-2016-140]\]. Partially covered SEMS might be superior to fully covered SEMS for prevention of migration, because mucosal hypertrophy at both uncovered ends of the stent may reduce the risk of migration. However, embedding of both ends of stents due to mucosal hyperplasia may cause difficulty in stent removal, which can be resolved by a "stent-in stent" strategy \[[@b22-ce-2016-140]\]. Recently, the use of tailored stents for post-bariatric surgery patients has been introduced, with some published results. For example, several case series of novel endoscopic stents reported successful management of postoperative staple line leak in patients who underwent SG. These stents were specially designed for the treatment of post-SG leak; both ends of the stent had high profile edges allowing a more firm anchorage, and longer length (23--24 cm) than conventional esophageal stents, enabling the stent to bypass the entire gastric sleeve \[[@b23-ce-2016-140],[@b26-ce-2016-140]\], or wider diameter (40 mm) to facilitate sufficient sealing of the leaks ([Fig. 1](#f1-ce-2016-140){ref-type="fig"}) \[[@b27-ce-2016-140]\]. Large-scale, randomized, prospective studies to compare conventional and tailored stents are needed.

In comparison to coverage to lead to natural sealing of a defect, complete closure of a leak or fistula is more challenging. Endoscopic injection of Histoacryl \[[@b28-ce-2016-140]\] or suturing devices \[[@b29-ce-2016-140]\] have been introduced to close post-bariatric leaks or revisions. Recently, the use of fibrin sealants or an over-the-scope clip (OTSC^®^; Ovesco AG, Tübingen, Germany) has been considered the main strategy to close a leak or fistula after bariatric surgery. After debridement or clearance of infected materials, an endoscopic injection of fibrin sealant may lead to the successful closure of chronic leaks or fistulas. Multiple sessions are usually required. Several small case series showed a 100% complete closure rate of post-bariatric leak or fistula when combined with surgical or endoscopic drainage, or stent insertion ([Table 2](#t2-ce-2016-140){ref-type="table"}) \[[@b30-ce-2016-140]-[@b34-ce-2016-140]\]. However, it is more difficult to achieve successful closure of defects in cases of refractory gastrocutaneous (GC) fistulas, and the application of tailored long fibrin Surgisis (Cook Biotech Inc., West Lafayette, IN, USA) using acellular matrix biomaterial originating from porcine small intestine to stimulate proliferation of fibroblasts and accelerate tissue repair has been reported to manage chronic GC fistulas after bariatric surgeries \[[@b33-ce-2016-140],[@b34-ce-2016-140]\]. However, complete closure rates were relatively lower, ranging from 40% to 80%, compared to other case series that included GJ leak \[[@b30-ce-2016-140],[@b32-ce-2016-140]\]. Combined endoscopic procedures, such as stenting, may enhance the effective implantation of fibrin plugs in fistular tracts, and thus lead to successful closure of GC fistulas \[[@b34-ce-2016-140]\].

A novel OTSC was designed to provide full-thickness closure of GI tract defects and was first introduced to manage massive bleeding or iatrogenic perforation \[[@b35-ce-2016-140]\]. Case reports regarding the application of OTSCs for successfully closing post-bariatric leaks and fistulas have been published \[[@b36-ce-2016-140],[@b37-ce-2016-140]\]. Recently, retrospective studies that enrolled larger numbers of patients have been reported and are summarized in [Table 3](#t3-ce-2016-140){ref-type="table"} \[[@b38-ce-2016-140]-[@b40-ce-2016-140]\]. It is notable that the clinical success rate of closure of leak or fistula was relatively high, ranging from 80% to 100%. In contrast, there were relatively few procedure-related complications. In one of the studies, closure of post-bariatric surgery leaks was achieved in all cases when OTSCs were applied with ultra-large expandable stents tailored for post-bariatric surgery leak (Mega stent, Taewoong Medical, Seoul, Korea) simultaneously or after stent removal \[[@b40-ce-2016-140]\]. However, it is premature to draw conclusions regarding the superiority of OTSCs over stent insertion or injection of fibrin glue, due to the lack of clinical outcomes and comparable studies. A recent retrospective study demonstrated that the application of OTSCs in patients with postoperative leakage, iatrogenic perforation, or spontaneous rupture of the upper GI tract resulted in higher clinical success rates, shorter hospital stay or treatment duration, and fewer complications, compared with insertion of fully covered SEMS \[[@b41-ce-2016-140]\]. However, it is difficult to apply this promising result in the management of post-bariatric leak, because the study did not include any cases of post-bariatric surgery.

STRICTURE
=========

Postoperative stricture is one of the most frequent complications of bariatric surgery. In cases of RYGB, stricture usually develops at the GJ anastomosis site, and is caused by the use of a circular rather than linear stapler, local ischemia, or inflammatory response \[[@b42-ce-2016-140]\]. The incisura angularis in SG is most vulnerable to postoperative stricture due to calibration of the sleeve over a tube that is too narrow or over-sewing of the staple line \[[@b43-ce-2016-140]\]. Recently, the incidence of postoperative stricture after bariatric surgery has been reported as 3.7%--7.8% at the GJ anastomosis site in RYGB \[[@b44-ce-2016-140]-[@b47-ce-2016-140]\]. However, several previous studies that included the early period of RYGB surgery cases (2000--2005) reported a relatively high incidence of postoperative stricture, ranging from 11% to 17% \[[@b48-ce-2016-140],[@b49-ce-2016-140]\]. Symptomatic stenosis after SG usually develops in the incisura angularis, and its incidence has been reported as 3.0%--3.5% \[[@b50-ce-2016-140],[@b51-ce-2016-140]\]. Significant stricture usually develops during the first 3 months of the postoperative period and, if clinically suspected, prompt diagnostic endoscopy and evaluation of stricture should be performed because endoscopic dilation of early postoperative stricture (within 90 days after surgery) is more effective than that of late stricture, which may lead to revisional surgery \[[@b52-ce-2016-140]\].

Since the introduction of TTS endoscopy, endoscopic balloon dilation of postoperative stricture has become generally accepted as an effective and safe therapeutic tool. Details of endoscopic balloon dilation procedures and clinical outcomes are summarized in [Table 4](#t4-ce-2016-140){ref-type="table"} \[[@b44-ce-2016-140]-[@b47-ce-2016-140],[@b49-ce-2016-140]-[@b51-ce-2016-140],[@b53-ce-2016-140]-[@b56-ce-2016-140]\]. Most of the significant strictures are found during the first 3 months after surgery, and a proportion of patients require repeat dilation, ranging from 2 to 4 sessions and even up to 7 sessions. The clinical success rate of balloon dilation, which indicates resolution of obstructive symptoms and passage of the endoscope without disturbance, was promising, with rates exceeding 90%. However, serious complications including perforation were reported in 2%--5% of cases. Recent data have indicated that the number of dilation sessions and ischemic segments in the stricture site are significant risk factors for perforation, while the ischemic segment and fistula have been positively associated with dilation failure \[[@b57-ce-2016-140]\]. In most strictures at the GJ anastomosis site in RYGB, the Controlled Radial Expansion (CRE) balloon (Boston Scientific Corporation, Marlborough, MA, USA) is effective when dilated up to 18 mm in diameter. However, a larger dilator is required in cases of complications such as gastric pouch stenosis or after SG. For example, Campos et al. showed that gastric pouch outlet stenosis due to silastic ring slippage after RYGB was successfully managed with preliminary dilation using a Savary dilator (Cook Biotech Inc.) or a CRE balloon dilated up to 20 mm, followed by definitive dilation using a 30-mm achalasia balloon \[[@b56-ce-2016-140]\]. Ogra et al. also reported successful treatment of fixed stenosis at the incisura angularis after SG with conventional CRE balloon dilation followed by use of a 30-mm achalasia balloon \[[@b51-ce-2016-140]\].

The placement of a stent at the stricture site has been also reported. However, the number of subjects and studies has been small, and only small case series have been reported up to now. The clinical success rate of stent insertion varies widely, ranging from 12.5% to 100% \[[@b58-ce-2016-140],[@b59-ce-2016-140]\]. It is necessary to evaluate the clinical feasibility and effectiveness of stent insertion for the treatment of post-bariatric surgery stricture by accumulating more clinical experiences with greater numbers of subjects.

GI HEMORRHAGE
=============

Generally, acute GI bleeding is more common in RYGB, in which its occurrence ranges from 1% to 5%, than in LAGB or SG, and it occurs more frequently in laparoscopic RYGB than open RYGB. Most bleeding occurs during the early postoperative phase within 3 days after surgery, and extraluminal bleeding accounts for half of the cases \[[@b43-ce-2016-140],[@b60-ce-2016-140],[@b61-ce-2016-140]\]. Tachycardia, decrease of hemoglobin or hematocrit, hematemesis, and melena are common clinical signs and symptoms, and the staple line is the most common specific source of bleeding, although generalized oozing without a specific source is also common \[[@b62-ce-2016-140]\]. If GI bleeding is considered extraluminal, abdominal imaging, such as a computed tomography (CT) scan, should be performed promptly to determine the bleeding site, and emergent surgical intervention is mandatory. If intraluminal bleeding is suspected at the gastrojejunostomy site, esophagogastroduodenoscopy may be performed for diagnosis, and a therapeutic endoscopic procedure can be performed at the same time, if feasible. However, it is challenging to diagnose jejunojejunostomy site bleeding, and push enteroscopy or balloon-assisted enteroscopy may be helpful \[[@b63-ce-2016-140]\]. Unfortunately, data from endoscopic homeostasis of post-bariatric surgical GI bleeding is still lacking. Jamil et al. showed that none of 24 patients who underwent endoscopic intervention required surgery to control GI hemorrhage, although 17% (5/24) patients required second- or third-look endoscopy with intervention \[[@b64-ce-2016-140]\]. Endoscopic procedures include epinephrine injection, heater probe, or clipping. However, heater probe therapy should be performed with caution, especially if bleeding originates from the staple line, due to the high risk of perforation \[[@b64-ce-2016-140]\].

In contrast to early postoperative GI hemorrhage, most late GI bleeding is caused by ulcers on the jejunal side near the GJ anastomosis site (i.e., marginal ulcers). The incidence of marginal ulcer is reported as 0.6%--16%, and most cases develop in the first 2--4 months after surgery \[[@b65-ce-2016-140]\]. Risk factors for marginal ulcers are multiple. Procedure-related factors include pouch orientation and size, staple line dehiscence, tension at the GJ anastomosis, and circular stapled anastomosis. Other major factors including long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), *Helicobacter pylori* infection, alcohol, smoking, and DM also influence the development of marginal ulcers \[[@b43-ce-2016-140]\]. *H. pylori* infection status should be tested, and eradication therapy performed if positive. The use of NSAIDs should be minimized or a physician should consider the concomitant use of proton pump inhibitors, mucosal protective agents, or sucralfate solution.

DILATION OF GJ ANASTOMOSIS OR GASTRIC POUCH
===========================================

After undergoing RYGB surgery, some patients suffer from weight regain and endoscopic examination reveals a significantly dilated GJ anastomosis or pouch. A previous study showed that gastric pouch length and stoma diameter were significantly enlarged in patients with weight regain compared to patients with sustained weight loss, and these measures were inversely correlated with excess weight loss. Furthermore, stoma diameter was an independent factor for weight regain after RYGB; the author suggested the upper limit of "normal" stoma diameter as 2.0 cm.66 Thus, revision of dilated gastric pouch or GJ anastomosis is an important issue for maintenance of the clinical effect of RYGB, and the endoscopic approach is safe and feasible.

The first endoscopic procedure developed to manage the dilated gastrojejunostomy was sclerotherapy. A sclerosing agent (usually 5% sodium morrhuate) is injected around the anastomosis site (1--2 cc/site, total 10--30 cc/session) and multiple sessions are performed until the diameter of the GJ anastomosis becomes 12 mm or smaller \[[@b67-ce-2016-140]\]. The clinical outcomes of sclerotherapy in patients with dilated GJ stoma are summarized in [Table 5](#t5-ce-2016-140){ref-type="table"} \[[@b68-ce-2016-140]-[@b72-ce-2016-140]\]. Overall, 1.3--2.0 sessions of sclerotherapy were performed and the GJ stoma was adjusted to 10--12 mm. Loss of weight after injection varied from 6.8 to 19.9 kg. The clinical success rate, defined as achievement of weight loss or weight stabilization with no further regain, was 58%--90%. At present, sclerotherapy appears to be a safe, technically feasible, and repeatable procedure with very few complications. However, its clinical efficacy in terms of weight loss is modest and long-term follow-up data with larger number of patients remain lacking \[[@b67-ce-2016-140]\]. Abu Dayyeh et al. published a large-scale retrospective study including 231 consecutive patients undergoing 575 sclerotherapy procedures; a greater amount of weight regain from nadir and multiple sclerotherapy sessions were significant predictors for better clinical outcomes with sclerotherapy \[[@b73-ce-2016-140]\]. However, the study had a relatively short-term follow-up of 12 months. Evaluation with a long-term follow-up period is needed.

Recently, endoscopic suturing devices have been developed for the treatment of dilated GJ anastomosis and gastric pouch. The Bard EndoCinch suturing system (C.R. BARD, Inc., Murray Hill, NJ, USA) is a device for use in the early period that attaches a suture capsule at the end of the endoscope to pull the tissues into the capsule and then sutures and ties using a needle and a knot pusher, tag pusher, and suture cutter. This device was first used for the treatment of patients with gastroesophageal reflux disorder \[[@b74-ce-2016-140]\], and then applied to the management of dilated GJ stoma after RYGB. Thompson et al. published a case series including 8 patients with weight regain and dilated GJ anastomosis after RYGB, and showed that 6 of 8 patients had 10 kg of weight loss at 4 months after the procedure, and the diameter of GJ anastomosis was reduced to 10 mm \[[@b75-ce-2016-140]\]. The same authors presented a double-blind, randomized, controlled, multicenter study of 77 subjects with post-RYGB weight regain and dilated gastrojejunostomy. With a mean number of 4 stiches, the mean weight loss at 4 months after the procedure was significantly greater in the endoscopic stich group compared with that in the sham group (4.7% vs. 1.9%, *p*=0.041) and the percentage of subjects who achieved weight loss or weight stabilization was also significantly higher in the endoscopic stich group (96% vs. 78%, *p*=0.041). However, the authors could not show a sustained significant difference at 6 months (4.2% vs. 1.9%, *p*=0.066) \[[@b76-ce-2016-140]\].

The StomaphyX™ endoluminal fastener and delivery system (EndoGastric Solutions, Redmond, WA, USA) is a novel endoscopic tissue approximation device. It utilizes 7-mm, 3-0 polypropylene H-fasteners to create endoluminal plication by suctioning full-thickness, serosa-to-serosa gastric wall and firing the polypropylene H-fasteners \[[@b77-ce-2016-140],[@b78-ce-2016-140]\]. Endoluminal suturing using StomaphyX™ has been applied for the management of dilated GJ anastomosis and pouch \[[@b77-ce-2016-140]-[@b79-ce-2016-140]\]. The percentage of effective weight loss, defined as weight loss divided by excess body weight, has varied from 20% to 47% \[[@b77-ce-2016-140],[@b79-ce-2016-140]\]. However, Goyal et al. reported disappointing long-term follow-up data, in which the best clinical outcomes of weight loss and reduction of GJ anastomosis and pouch were achieved at 6 months after the procedure but were diminished at the end of follow-up at 41 months ([Table 6](#t6-ce-2016-140){ref-type="table"}) \[[@b78-ce-2016-140]\]. Another second-generation endoscopic suturing device is the restorative obesity surgery endoscopic (ROSE) device, which contains a multi-lumen system to work as operating channels. This Incisionless Operating Platform (IOP) enables the creation of a full-thickness tissue plication using a tissue approximator (g-Prox), tissue grasper (g-Lix), and expandable tissue anchoring system (g-Cath) \[[@b80-ce-2016-140]\]. The short-term clinical outcomes have been acceptable, with 50%--70% reduction in the diameter of GJ anastomosis and 36%--55% reduction of pouch size, 4.2--8.8 kg weight loss, 18%--23% excess weight loss, and only minor complications ([Table 6](#t6-ce-2016-140){ref-type="table"}) \[[@b80-ce-2016-140]-[@b84-ce-2016-140]\]. However, the most remarkable shortcomings of previous studies of the ROSE procedure for post-RYGB dilation are the lack of long-term follow-up data and the risk that weight regain may exist. Another problem is that the aforementioned novel devices are no longer clinically available, and more efforts need to be made to improve the long-term clinical efficacy and durability.

Meanwhile, the application of OTSC for revision of dilated GJ anastomosis and management of post-RYGB weight regain has also been reported. Heylen et al. applied the OTSC to 94 patients with RYGB and weight gain and dilated gastrojejunostomy, and reported that the diameter of GJ anastomosis was reduced from 45 mm to 8 mm by 1 or 2 sessions of OTSC clipping, with BMI dropping from 45.8 kg/m^2^ before the procedure to 27.4 kg/m^2^ at 1 year after the procedure \[[@b85-ce-2016-140]\]. Further clinical experiences and data are required to support this reported efficacy.

BAND EROSION
============

The use of a silastic band or ring is very common in vertical gastroplasty or LAGB, and even in RYGB, and it may cause several complications, such as band slippage, gastric pouch outlet stenosis, and band erosion during its long-term placement around the upper stomach just below the EGJ. Among these complications, band erosion, the late process of intragastric band migration, may lead to loss of satiety, weight regain, and even infection at the port site, although most patients are asymptomatic \[[@b86-ce-2016-140]\]. The incidence of band erosion is variable and has been reported as 0.3%--1.9% among large-scale studies that included more than 100 patients, and a recent systemic review of 15,775 patients who underwent LAGB reported an overall incidence of 1.5% \[[@b87-ce-2016-140]\].

Once band migration and erosion occur, removal of the band should be considered owing to the possibility of complications. Surgical removal using the laparoscopic transabdominal approach is the classic method. However, endoscopic removal is feasible after extraction of the adjustable port via subcutaneous exploration. This endoscopic approach has the advantage over surgery in terms of avoiding serious morbidity or secondary surgery. However, it should be performed in cases when \>50% of the intragastric band is visible to avoid serious complications, such as bleeding or intra-abdominal or subcutaneous infection \[[@b43-ce-2016-140]\]. To induce and accelerate the process of band erosion, temporary insertion of fully covered stents may be considered for 1--2 weeks for induction of pressure necrosis of the gastric wall between the band and stent \[[@b88-ce-2016-140]\], or cutting of the tissue bridge to release the intragastric band using a standard papillotome and argon plasma coagulation (APC) \[[@b89-ce-2016-140]\]. Recently, Marins Campos et al. reported that induction of intragastric band erosion using a self-expandable plastic stent was effective for removal of a non-eroded band in 41 patients with banded RYGB who experienced food intolerance due to banding of the gastric pouch.90 Successful removal of the band was achieved in all patients, after which food intolerance was improved in 32 patients (78.0%), and 9 patients (22.0%) required additional endoscopic balloon dilation after removal of the stent \[[@b90-ce-2016-140]\].

When sufficient intragastric band migration and erosion is observed, cutting of the band should be performed, various devices have been used for endoscopic cutting, including APC \[[@b91-ce-2016-140]\] or endoscopic scissors \[[@b92-ce-2016-140]\]. The metallic thread of the gastric-band-cutter device (Agency for Medical Innovations GmbH, Feldkirch, Austria) is also an effective option for cutting the bands. A metallic thread is introduced through the working channel to form a loop around the band, pulled back to the mouth to connect both ends of the metallic thread to the external cutting device, and cut by twisting the handle of the external gastric-band-cutter (tourniquet technique) \[[@b93-ce-2016-140],[@b94-ce-2016-140]\]. Once the band is successfully cut, extraction of the band can be easily performed using a snare or large grasping forceps. The technical success rate of endoscopic removal of a gastric band has been reported to be 92%--95% in two large-scale retrospective studies that each included more than 50 cases \[[@b95-ce-2016-140],[@b96-ce-2016-140]\]. The most worrisome complication is pneumoperitoneum, which can be treated with conservative management, but which sometimes requires laparoscopic surgery \[[@b94-ce-2016-140],[@b95-ce-2016-140]\].

CONCLUSION AND FUTURE PERSPECTIVES
==================================

Bariatric surgery, which currently plays a pivotal role in the curative management of morbid obesity, has mainly been performed in Western countries. However, as the numbers of patients with DM and metabolic syndrome increase, bariatric surgery is being performed more and more frequently in East Asia, and the associated complications are expected to increase accordingly \[[@b97-ce-2016-140]\]. Thus, endoscopists must be familiar with the process and types of bariatric surgery, the main complications, and the feasibility and safety of the endoscopic approach to successfully manage post-bariatric complications. Furthermore, an optimal approach should be considered first through close collaboration and thorough discussion with bariatric surgeons to avoid serious morbidity. Meanwhile, primary endoscopic gastroplasty is being attempted with the use of various novel endoscopic suturing devices \[[@b98-ce-2016-140]\], and endoscopists are expected to become the first-line providers in the optimal management of serious obesity and refractory DM in the near future.
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![Tailored stent for management of post-bariatric surgery leak. A sleeve-customized self-expandable metal stent (SEMS) with a high edge profile, allowing a more firm anchorage and longer length (23--24 cm) than conventional esophageal stent to bypass the entire gastric sleeve (Mega stent, Taewoong, Seoul, Korea).](ce-2016-140f1){#f1-ce-2016-140}

###### 

Clinical Outcomes of Endoscopic Stent Insertion for the Management of Post-Bariatric Leaks and Fistulas

  Study                                             Type of stent   Number of subjects   Type of bariatric surgery                                 Duration of stenting (days)   Clinical success rate % (n/n)   Complications (*n*)
  ------------------------------------------------- --------------- -------------------- --------------------------------------------------------- ----------------------------- ------------------------------- ------------------------------------------------------------------
  Salinas et al. (2006) \[[@b16-ce-2016-140]\]      SEMS            17                   RYGB                                                      Not presented                 94 (16/17)                      Esophageal mucosal tear (2), migration (1)
  Eisendrath et al. (2007) \[[@b17-ce-2016-140]\]   PSEMS           21                   RYGB (8), SG (12), BPD (1)                                21                            81 (17/21)                      Migration (1), stricture (2)
  Bège et al. (2011) \[[@b18-ce-2016-140]\]         Not presented   22                   RYGB, SG                                                  64                            70 (18/22)                      Migration (13)
  Freedman et al. (2013) \[[@b19-ce-2016-140]\]     Not presented   35                   RYGB                                                      ≤14 days in 80%               86 (30/35)                      Migration (8)
  El Mourad et al. (2013) \[[@b20-ce-2016-140]\]    PSEMS           47                   SG (24), RYGB (12), LAGB (4), LMGB (3), BPD (2), DS (1)   45                            87 (41/47)                      Migration (7), perforation (1)
  Alazmi et al. (2014) \[[@b21-ce-2016-140]\]       SEMS/SEPS       17                   SG                                                        42                            76 (13/17)                      Minor bleeding (2), dysphagia (3), migration (1)
  Murino et al. (2015) \[[@b22-ce-2016-140]\]       PSEMS           91                   SG (55), RYGB (36)                                        69                            81 (74/91)                      Esophageal stricture (13), migration (7), perforation (7)
  Fishman et al. (2015) \[[@b23-ce-2016-140]\]      S-SEMS          26                   SG                                                        28                            65 (17/26)                      Migration (7), severe bleeding (1), severe intolerance (4)
  Southwell et al. (2016) \[[@b24-ce-2016-140]\]    PSEMS           21                   SG                                                        ≤14 days in 67%               95 (20/21)                      Migration (10), severe intolerance (5), esophageal stricture (2)

SEMS, self-expandable metal stent; PSEMS, partial-covered self-expandable metallic stent; SEPS, self-expandable plastic stent; S-SEMS, sleeve-customized self-expandable metal stents; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; BPD, biliopancreatic diversion; LAGB, laparoscopic adjustable gastric banding; LMGB, laparoscopic mini gastric bypass; DS, duodenal switch.

###### 

Clinical Outcomes of Endoscopic Injection of Fibrin Sealant for Closure of Post-Bariatric Leaks

  Study                                               Number of subjects   Combined/precedent procedures          Type of bariatric surgery   Complete closure rate (%)   Time for closure (days)   Complications (*n*)
  --------------------------------------------------- -------------------- -------------------------------------- --------------------------- --------------------------- ------------------------- ---------------------------------------------
  Kowalski et al. (2007) \[[@b30-ce-2016-140]\]       5                    Open drainage                          LRYGB                       100                         4                         None
  Papavramidis et al. (2008) \[[@b31-ce-2016-140]\]   3                    Radiologic drainage (1)                SG, BPD                     100                         Not presented             Not presented
  Victorzon et al. (2013) \[[@b32-ce-2016-140]\]      6                    Stent (1), laparoscopic drainage (5)   LRYGB                       100                         19.5                      Necrotizing pancreatitis (1), stricture (1)
  Maluf-Filho et al. (2009) \[[@b33-ce-2016-140]\]    25                   None                                   RYGB                        80                          Not presented             None
  Toussaint et al. (2009) \[[@b34-ce-2016-140]\]      5                    Stent (3)                              RYGB/SG                     40                          Not presented             None

LRYGB, laparoscopic Roux-en-Y gastric bypass; SG, sleeve gastrectomy; BPD, biliopancreatic diversion; RYGB, Roux-en-Y gastric bypass.

###### 

Clinical Outcomes of Over-the-Scope Clip for Closure of Post-Bariatric Leaks

  Study                                         Number of subjects   Combined/precedent procedures                     Type of bariatric surgery   Complete closure rate (%)   Time for closure (days)   Complications (*n*)
  --------------------------------------------- -------------------- ------------------------------------------------- --------------------------- --------------------------- ------------------------- ----------------------------------------------------------------------
  Mercky et al. (2015) \[[@b38-ce-2016-140]\]   19                   Stent (7)                                         LSG (18), RYGB              84                          Not presented             Stenosis (1), anchor migration (1), fistula edges torn by anchor (1)
  Keren et al. (2015) \[[@b39-ce-2016-140]\]    26                   Stent (6), biologic glue (1), argon cautery (1)   LSG                         80                          32                        None
  Shehab et al. (2016) \[[@b40-ce-2016-140]\]   12                   Mega stent (12)                                   RYGB, SG                    100                         Not presented             Not presented

LSG, laparoscopic sleeve gastrectomy; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.

###### 

Clinical Outcomes of Endoscopic Ballooning for Management of Post-Bariatric Stricture

  Study                                              Type of bariatric surgery                            Number of subjects   Time to diagnosis (days)   Balloon diameter (type, mm)         Number of session   Clinical success rate (%)   Complications (*n*, %)
  -------------------------------------------------- ---------------------------------------------------- -------------------- -------------------------- ----------------------------------- ------------------- --------------------------- ------------------------------
  Carrodeguas et al. (2006) \[[@b44-ce-2016-140]\]   RYGB                                                 94                   52.7                       CRE, up to 16.5                     1--4                100                         Perforation (2, 2.1)
  Peifer et al. (2007) \[[@b45-ce-2016-140]\]        RYGB                                                 43                   49.7                       CRE, 15.5                           1--2                93                          None
  Ukleja et al. (2008) \[[@b46-ce-2016-140]\]        RYGB                                                 61                   60                         CRE, up to 18                       1--5                100                         Perforation (3, 4.9)
  Da Costa et al. (2011) \[[@b47-ce-2016-140]\]      RYGB                                                 105                  90                         CRE, up to 16                       1--4                100                         Perforation (3, 1.8)
  Ahmad et al. (2003) \[[@b53-ce-2016-140]\]         RYGB                                                 14                   81                         CRE, up to 18                       1--7                100                         None
  Go et al. (2004) \[[@b54-ce-2016-140]\]            RYGB                                                 38                   54                         CRE, up to 16                       1--6                95                          Perforation (1, 2.6)
  Rossi et al. (2005) \[[@b49-ce-2016-140]\]         RYGB                                                 38                   Not presented              CRE, up to 15                       1--4                100                         Nausea and vomiting (1, 2.6)
  Catalano et al. (2007) \[[@b55-ce-2016-140]\]      RYGB                                                 26                   38                         CRE, up to 15                       1--7                96                          None
  Campos et al. (2010) \[[@b56-ce-2016-140]\]        RYGB^[a)](#tfn1-ce-2016-140){ref-type="table-fn"}^   35                   Not presented              Achalasia, 30                       1--4                100                         Hemorrhage (1, 2.8)
  Parikh et al. (2012) \[[@b50-ce-2016-140]\]        SG                                                   8                    48                         CRE, 16                             1--2                100                         Not presented
  Ogra et al. (2015) \[[@b51-ce-2016-140]\]          SG                                                   26                   49                         CRE, up to 20 Achalasia, up to 30   1--4                100                         None

RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; CRE, Controlled Radial Expansion.

Gastric pouch outlet stenosis due to ring slippage.

###### 

Clinical Outcomes of Endoscopic Sclerotherapy for Management of Dilated Gastrojejunal Anastomosis after Roux-en-Y Gastric Bypass

  Study                                             Number of subjects   Number of session   Follow-up period (month)   Diameter of GJA (mm)^[a)](#tfn2-ce-2016-140){ref-type="table-fn"}^   Loss of weight (kg)                                   Clinical success rate (%)   Complications
  ------------------------------------------------- -------------------- ------------------- -------------------------- -------------------------------------------------------------------- ----------------------------------------------------- --------------------------- ---------------------------
  Spaulding (2003) \[[@b68-ce-2016-140]\]           20                   1.3                 6                          9--10                                                                --6.8                                                 75                          Vomiting, epigastric pain
  Spaulding et al. (2007) \[[@b69-ce-2016-140]\]    32                   1.8                 \>12                       10                                                                   --0.39 / month                                        90.7                        Not presented
  Catalano et al. (2007) \[[@b70-ce-2016-140]\]     28                   2.3                 18                         12.7                                                                 --19.9                                                64                          Stenosis
  Loewen et al. (2008) \[[@b71-ce-2016-140]\]       71                   1.6                 12                         Not presented                                                        --8.6                                                 72                          Epigastric pain
  Abu Dayyeh et al. (2012) \[[@b73-ce-2016-140]\]   231                  2                   12                         Not presented                                                        --4.5^[b)](#tfn3-ce-2016-140){ref-type="table-fn"}^   76                          Bleeding, pain
  Giurgius et al. (2014) \[[@b72-ce-2016-140]\]     48                   2                   22                         Not presented                                                        --7.2                                                 58                          Not presented

GJA, gastrojejunal anastomosis.

After sclerotherapy.

Weight loss at 6 months after sclerotherapy.

###### 

Clinical Outcomes of Endoscopic Suturing and Plication for Management of Dilated Gastrojejunal Anastomosis or Gastric Pouch after Roux-en-Y Gastric Bypass

  Study                                          Number of subjects   Follow-up period (month)   Number of plications or anchors   Reduction of GJA or pouch (%)   Loss of weight (kg)                                         Excess weight loss (%)                                   Complications
  ---------------------------------------------- -------------------- -------------------------- --------------------------------- ------------------------------- ----------------------------------------------------------- -------------------------------------------------------- ----------------------------------------------------------
  StomaphyX                                                                                                                                                                                                                                                                             
  Mikami et al. (2010) \[[@b77-ce-2016-140]\]    39                   12                         17                                Not presented                   --10                                                        19.5                                                     Dumping syndrome, pigastric pain
  Ong'uti et al. (2013) \[[@b79-ce-2016-140]\]   27                   12                         4                                 Not presented                   Not presented                                               47                                                       Reflux
  Goyal et al. (2013) \[[@b78-ce-2016-140]\]     59                   41                         21                                47 (GJA), 20 (pouch)            --3.8→--1.7^[a)](#tfn4-ce-2016-140){ref-type="table-fn"}^   11.5→4.3^[a)](#tfn4-ce-2016-140){ref-type="table-fn"}^   None
  Incisionless Operating Platform                                                                                                                                                                                                                                                       
  Ryou et al. (2009) \[[@b80-ce-2016-140]\]      5                    3                          7.6                               70 (GJA), 55 (pouch)            --7.8                                                       Not presented                                            Nausea and vomiting
  Mullady et al. (2009) \[[@b81-ce-2016-140]\]   20                   3                          5                                 65 (GJA), 36 (pouch)            --8.8                                                       Not presented                                            Bloating, sore throat
  Borao et al. (2010) \[[@b82-ce-2016-140]\]     21                   6                          5.3                               53 (GJA), 41 (pouch)            --7.8                                                       18                                                       Not presented
  Horgan et al. (2010) \[[@b83-ce-2016-140]\]    116                  6                          5.9                               50 (GJA), 44 (pouch)            --7.8                                                       21.5                                                     Pharyngitis (41%), nausea and vomiting (12%), pain (11%)
  Raman et al. (2011) \[[@b84-ce-2016-140]\]     37                   4.7                        Not presented                     52 (GJA)                        --4.2                                                       23.5                                                     Abdominal pain

GJA, gastrojejunal anastomosis.

Difference between the best outcomes and at the data at the end of follow-up.
